Akkermansia muciniphila, a bacterium that lives in the mucus lining of the gut, directly stimulates the release of GLP-1, a hormone central to blood sugar regulation and appetite control. It does this largely through a secreted protein called P9, identified in 2021, which triggers intestinal cells to produce more GLP-1. But the relationship runs in both directions: GLP-1-based medications like semaglutide and dulaglutide appear to reshape the gut microbiome in ways that increase Akkermansia abundance, creating a feedback loop that researchers are only beginning to map. The interplay between this single bacterial species, a key metabolic hormone, and the broader microbial community offers a window into why gut health and metabolic health are so tightly linked.
What Akkermansia Actually Does in the Gut
Akkermansia muciniphila is one of the few well-studied species in the phylum Verrucomicrobia. It lives in the mucus layer that coats the intestinal lining, and its primary food source is mucin, the glycoprotein that gives mucus its gel-like consistency. That might sound destructive, but under normal conditions the relationship is symbiotic: as Akkermansia breaks down mucin, it stimulates goblet cells to produce fresh mucus, keeping the barrier thick and functional. The bacterium was first isolated and characterized in the early 2000s and has since become one of the most studied members of the human gut microbiome.
Akkermansia typically makes up somewhere between one and five percent of the total gut bacterial population in healthy adults. Its abundance tends to be lower in people with obesity and type 2 diabetes. A large study analyzing the gut microbiomes of over 600 people found that Akkermansia was among the genera significantly decreased in individuals with obesity.1Cell Host & Microbe. Gut Microbiome Diversity and Composition in Obesity and Type 2 Diabetes Early mouse research demonstrated that Akkermansia abundance was inversely tied to diet-induced obesity and that administering the bacterium could reverse several metabolic problems caused by high-fat diets.2PubMed Central. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity
The P9 Protein and GLP-1 Secretion
The most concrete molecular link between Akkermansia and GLP-1 centers on a protein called P9. Researchers identified P9 as a novel protein secreted by Akkermansia muciniphila that directly stimulates GLP-1 secretion from intestinal L cells, the specialized cells in the gut lining responsible for producing this hormone.3PubMed. A newly identified protein from Akkermansia muciniphila stimulates GLP-1 secretion GLP-1 plays a well-known role in signaling the pancreas to release insulin after meals and in slowing gastric emptying, both of which help regulate blood sugar. It also acts on the brain to reduce appetite, which is why GLP-1-based drugs have become blockbuster treatments for diabetes and obesity.
The P9 discovery was significant because it moved the conversation beyond vague associations between Akkermansia and metabolic health toward a specific, testable mechanism. Subsequent work confirmed the finding by engineering a different bacterium, Lactococcus lactis, to produce the P9 protein. When this engineered strain’s secretions were exposed to human intestinal L cells in the lab, GLP-1 production increased, replicating the effect without any Akkermansia present at all.4PubMed. Heterologous expression of P9 from Akkermansia muciniphila increases the GLP-1 secretion of intestinal L cells That experiment mattered because it isolated P9 as a sufficient trigger for GLP-1 release, ruling out the possibility that something else about Akkermansia’s presence was responsible.
Akkermansia also produces another well-studied molecule, the outer membrane protein Amuc_1100, which activates Toll-like receptor 2 (TLR2) and reproduces many of the bacterium’s beneficial effects on metabolism and gut barrier function. Intriguingly, Amuc_1100 is heat-stable, meaning even pasteurized (dead) Akkermansia retains this activity.5Cell Metabolism. A newly identified protein from Akkermansia muciniphila stimulates GLP-1 secretion This finding has been central to the development of pasteurized Akkermansia supplements, since live bacteria are far harder to manufacture, store, and regulate.
The Bidirectional Loop With GLP-1 Drugs
The relationship between Akkermansia and GLP-1 is not one-directional. When people take GLP-1 receptor agonists like semaglutide or dulaglutide for diabetes or weight loss, these drugs reshape the gut microbiome in measurable ways. A systematic review of the evidence found that dulaglutide led to significant increases in Akkermansia, Bacteroides, and Ruminococcus, all genera associated with healthier metabolic profiles. Semaglutide also increased Akkermansia muciniphila abundance, although it reduced overall microbial diversity.6PubMed Central. Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review
This creates an interesting feedback scenario. Akkermansia produces P9, which stimulates GLP-1 secretion. GLP-1 drugs mimic or amplify the effects of that hormone. And the drugs, in turn, seem to create gut conditions that favor Akkermansia’s growth. The broader microbial community participates too: gut bacteria produce short-chain fatty acids and bile acid derivatives that modulate GLP-1 secretion, while GLP-1 agonists reshape that same microbial community, influencing metabolic outcomes that go beyond the drugs’ direct hormonal effects.7PubMed Central. GLP-1 agonists and the gut microbiome: A bidirectional relationship
How much of the clinical benefit of drugs like semaglutide comes from their direct pharmacological action and how much from their microbiome-reshaping effects is still an open question. But the existence of this loop suggests that a person’s starting gut composition could influence how well they respond to GLP-1 therapy, and that the microbiome changes induced by treatment might sustain some benefits even after the drug is stopped.
What Clinical Trials of Pasteurized Akkermansia Show
The heat stability of Akkermansia’s key proteins made pasteurized preparations a realistic product. Two recent controlled trials have tested pasteurized Akkermansia muciniphila (a specific strain designated MucT) in humans with overweight, obesity, or metabolic syndrome, and both produced encouraging results.
In a weight maintenance trial, participants who had already lost weight through calorie restriction were randomized to receive either pasteurized MucT or placebo during a maintenance phase. The MucT group regained only about 1.2 kg on average, compared to 3.2 kg in the placebo group. The net additional weight loss from baseline to the end of the maintenance period was about 3.1 kg greater in the MucT group. No serious adverse events related to treatment were observed.8Nature Medicine. Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial
A larger multicenter trial enrolled 142 adults with metabolic syndrome across sites in Ireland and Germany. After three months of daily pasteurized MucT supplementation, exploratory analyses found improvements in liver-based insulin sensitivity of about 12 percent in prediabetic participants. The MucT group also showed increased GLP-1 excursion after an oral glucose challenge compared to placebo, confirming that the supplement boosted GLP-1 production in living humans, not just in lab cells or mice.9PubMed Central. Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome: impact of low baseline gut Akkermansia levels One particularly telling finding from this trial was that benefits were most pronounced in people who started with low levels of Akkermansia in their gut, suggesting these individuals were “truly in need” of the intervention.
Both trials noted that initial Akkermansia abundance predicted how well participants responded. This is consistent with the broader pattern: if you already have plenty of the bacterium, adding more may not do much. If your levels are depleted, supplementation seems to fill a genuine gap.
How Akkermansia Shapes the Wider Gut Ecosystem
Akkermansia does not operate in isolation. Its mucin-degrading activity generates byproducts, including short-chain fatty acids like propionate, that feed other beneficial bacteria and influence the chemistry of the gut environment. By helping maintain a thick, healthy mucus layer, Akkermansia also supports the physical barrier between gut bacteria and the intestinal lining. In mouse models, Akkermansia administration increased the expression of tight junction proteins, the molecular “rivets” that hold intestinal cells together, which reduced gut permeability and lowered circulating levels of bacterial endotoxins that drive systemic inflammation.10PubMed. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice
Akkermansia also interacts with bile acid metabolism. Research in diabetic mice has shown that the bacterium regulates bile salt hydrolase activity, which shifts the composition of bile acids in the gut. One downstream effect is altered signaling through bile acid receptors (FXR and TGR5) that govern fat and sugar metabolism.11ACS Publications (J. Agric. Food Chem.). Akkermansia-Mediated BSH Regulation Alleviates Diabetic Dyslipidemia via the TCA-FXR/TGR5 Axis: Unraveling the Antidiabetic Mechanism of RKP These bile acid receptors are themselves linked to GLP-1 secretion, adding yet another route through which Akkermansia can nudge the hormone upward. The picture that emerges is not a single pathway but a web of interconnected effects on mucus, barrier integrity, bile acids, and hormonal signaling.
Dietary Ways to Boost Akkermansia Naturally
Not everyone wants or needs a supplement. Certain foods and dietary components have been shown to increase Akkermansia abundance in the gut, at least in animal models. The strongest evidence involves polyphenols, the antioxidant compounds found in colorful fruits, tea, and wine. A cranberry extract rich in polyphenols prevented diet-induced obesity in mice while producing a dramatic increase in Akkermansia levels.12PubMed Central. Triggering Akkermansia with dietary polyphenols: A new weapon to combat the metabolic syndrome? A broader review of plant-based dietary strategies confirmed that polyphenols, alkaloids, capsaicin, and certain plant-derived carbohydrates can all significantly raise Akkermansia abundance.13Journal of Functional Foods. Dietary strategies to promote the abundance of intestinal Akkermansia muciniphila, a focus on the effect of plant extracts
In practical terms, this translates to a diet rich in berries, grapes, green tea, and spicy foods. Dietary fiber also supports Akkermansia indirectly: while the bacterium feeds on mucin rather than fiber directly, a fiber-rich diet promotes mucus production and supports the broader microbial ecosystem that keeps Akkermansia’s neighborhood habitable. This distinction matters because the bacterium’s behavior changes depending on context, a point worth understanding before assuming more Akkermansia is always better.
When More Akkermansia Is Not Better
The narrative around Akkermansia is overwhelmingly positive, but researchers have flagged important caveats. Akkermansia’s defining activity, degrading mucin, can become a liability under certain conditions. When dietary fiber is very low or when the gut microbiome is already disrupted, Akkermansia may overconsume mucin faster than the body can replenish it, thinning the mucus barrier and increasing vulnerability to inflammation, infection, and pathogenic overgrowth.14PubMed Central. Breaking down barriers: is intestinal mucus degradation by Akkermansia muciniphila beneficial or harmful?
This context dependency is reinforced by research in malignant intestinal environments. In models where the gut lining was already compromised, high Akkermansia abundance was associated with intestinal barrier damage from excessive mucin consumption.15PubMed Central. Excessive consumption of mucin by over-colonized Akkermansia muciniphila promotes intestinal barrier damage during malignant intestinal environment The takeaway is not that Akkermansia is dangerous, but that its effects depend on the surrounding conditions. In a healthy gut with adequate fiber and normal mucus turnover, it plays a protective role. In a depleted or diseased gut, the same mucin-degrading behavior could worsen an already fragile barrier.
Given these findings, the use of Akkermansia supplements should be evaluated individually rather than treated as universally beneficial.16PubMed Central. A Critical Perspective on the Supplementation of Akkermansia muciniphila: Benefits and Harms People with inflammatory bowel disease, active gut infections, or severely compromised intestinal barriers may not be ideal candidates, even though the majority of clinical data in metabolically unhealthy but otherwise typical adults has been reassuring.
Not All Akkermansia Strains Are the Same
One complication that often gets glossed over in popular discussion is strain diversity. A genomic and phenotypic analysis of 71 human Akkermansia muciniphila isolates revealed that the species falls into distinct phylogroups with meaningfully different traits, including differences in oxygen tolerance, ability to adhere to intestinal cells, iron and sulfur metabolism, and tendency to form bacterial aggregates.17mBio. Genotypic and Phenotypic Diversity among Human Isolates of Akkermansia muciniphila These are not trivial differences. Oxygen tolerance determines where in the gut a strain can survive. Adherence capacity affects how well it colonizes. Metabolic capabilities shape how it interacts with its microbial neighbors.
This diversity means that findings from one strain, like the MucT strain used in the clinical trials described above, may not generalize to every strain of Akkermansia muciniphila floating around in your gut or in a commercial supplement. The field has not yet mapped which phylogroups produce the most P9, which are best at stimulating GLP-1, or which are most likely to cause problems under low-fiber conditions. For now, the most clinically tested strain is MucT, and extrapolating to other strains requires caution.
Akkermansia Across the Lifespan
Akkermansia abundance is not static throughout life. It colonizes the gut early in infancy and its levels fluctuate with diet, health status, and age. A systematic review of gut microbiome studies across age groups found that Akkermansia was the most frequently reported genus to be elevated in the oldest-old adults, the people who reach their late 80s and beyond. The review associated Akkermansia, along with a few other microbial genera, with reduced inflammation, lower adiposity, and preserved metabolic and cognitive function in aging populations.18PubMed Central. The Gut Microbiome, Aging, and Longevity: A Systematic Review
Whether Akkermansia actively promotes longevity or simply thrives in healthier guts that happen to belong to long-lived people is unresolved. But the association is consistent enough to raise genuine interest. If Akkermansia helps maintain gut barrier integrity, keep inflammation in check, and support GLP-1 signaling over decades, it could plausibly contribute to the metabolic resilience that distinguishes healthy aging from the chronic disease trajectory. The people who seem to benefit most from supplementation, those with low baseline Akkermansia levels, may also be the ones whose age-related metabolic decline has eroded this microbial ally furthest. That hypothesis is still being tested, but it aligns with the clinical trial data showing the largest effects in people who started with the least Akkermansia.